MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED (MVP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MVP - MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.15
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.405

28 May
2024

0.010

OPEN

$0.40

2.53%

HIGH

$0.42

228,605

LOW

$0.40

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

Last ex-div: 05/03 - ex-div 2c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-6.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx32.3 M
Book Value Per Share xxxxxxxxxxxxxxx94.2
Net Operating Cash Flow xxxxxxxxxxxxxxx-16.5 M
Net Profit Margin xxxxxxxxxxxxxxx-17.35 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-8.09 %
Return on Invested Capital xxxxxxxxxxxxxxx-7.83 %
Return on Assets xxxxxxxxxxxxxxx-5.32 %
Return on Equity xxxxxxxxxxxxxxx-8.09 %
Return on Total Capital xxxxxxxxxxxxxxx-28.16 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-18.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx3 M
Goodwill - Gross xxxxxxxxxxxxxxx9 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx25 M
Price To Book Value xxxxxxxxxxxxxxx0.82

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx7.7 M
Capex % of Sales xxxxxxxxxxxxxxx23.70 %
Cost of Goods Sold xxxxxxxxxxxxxxx35 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx18 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

MVP STOCK CHART